ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma

• Main Authors: Yun Zou (Author), Wenzhi Li (Author), Juan Zhou (Author), Jin Zhang (Author), Yiran Huang (Author), Zhong Wang (Author)
• Formato: Livro
• Publicado em: Elsevier, 2019-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The clinical efficiency of everolimus, an mammalian target of rapamycin (mTOR) inhibitor, is palliative as sequential or second-line therapy for renal cell carcinoma (RCC). However, the limited response of everolimus in RCC remains uncertain. In the present study, everolimus-resistant RCC models wer...